Drug Profile

TNX 1500

Alternative Names: Anti-CD154 monoclonal antibody-Tonix Pharmaceuticals; AntiCD40 ligand antibody; TNX-1500

Latest Information Update: 21 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tonix Pharmaceuticals Holding Corp
Class Monoclonal antibodies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Autoimmune disorders; Graft-versus-host disease; Transplant rejection

Most Recent Events

09 Apr 2025 Tonix Pharmaceuticals Holding Corp and Makana Therapeutics enters into a research agreement for TNX 1500
07 Feb 2025 Tonix Pharmaceuticals plans a meeting with US FDA for transplant rejection in
07 Feb 2025 Pharmacodynamics, pharmacokinetics and adverse events data from a phase I in Transplant rejection released by Tonix Pharmaceuticals

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com